Trientine Tetrahydrochloride Patent Expiration

Trientine Tetrahydrochloride is Used for the treatment of stable Wilson's disease in adult patients who are already de-coppered and tolerant to penicillamine. It was first introduced by Orphalan Sa in its drug Cuvrior on Apr 28, 2022.


Trientine Tetrahydrochloride Patents

Given below is the list of patents protecting Trientine Tetrahydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Cuvrior US10988436 Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use May 03, 2039 Orphalan
Cuvrior US11072577 Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use May 03, 2039 Orphalan



Trientine Tetrahydrochloride's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List